No connection

Search Results

BLLN vs LEGN

BLLN
BillionToOne, Inc.
BEARISH
Price
$74.08
Market Cap
$3.41B
Sector
Healthcare
AI Confidence
85%
LEGN
Legend Biotech Corporation
BEARISH
Price
$18.16
Market Cap
$3.36B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BLLN
569.85
LEGN
--
Forward P/E
BLLN
82.77
LEGN
15.79
P/B Ratio
BLLN
7.07
LEGN
3.35
P/S Ratio
BLLN
11.16
LEGN
3.26
EV/EBITDA
BLLN
131.6
LEGN
-48.64

Profitability

Gross Margin
BLLN
68.32%
LEGN
20.03%
Operating Margin
BLLN
10.76%
LEGN
-6.72%
Profit Margin
BLLN
0.96%
LEGN
-28.85%
ROE
BLLN
2.3%
LEGN
-29.06%
ROA
BLLN
2.14%
LEGN
-5.01%

Growth

Revenue Growth
BLLN
113.1%
LEGN
64.2%
Earnings Growth
BLLN
--
LEGN
--

Financial Health

Debt/Equity
BLLN
0.23
LEGN
0.41
Current Ratio
BLLN
11.69
LEGN
1.96
Quick Ratio
BLLN
11.21
LEGN
1.88

Dividends

Dividend Yield
BLLN
--
LEGN
--
Payout Ratio
BLLN
0.0%
LEGN
0.0%

AI Verdict

BLLN BEARISH

BLLN exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about bankruptcy risk. The stock trades at a steep valuation, with a P/E of 569.85 and Price/Sales of 11.16, far exceeding sector averages and the Graham Number of $5.54, suggesting significant overvaluation. Despite explosive revenue growth of 113.1% YoY, earnings remain weak (Profit Margin 0.96%) and inconsistent, with a recent -83.5% Q/Q EPS decline and mixed earnings surprises. Insider activity is neutral with no recent trades, and technical momentum is bearish, reflecting prolonged underperformance. The combination of extreme valuation, deteriorating earnings quality, and lack of dividend support undermines long-term conviction.

Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Exceptional revenue growth of 113.1% YoY, outpacing sector average of 125.63%
High gross margin of 68.32% reflects strong pricing power and cost control
Risks
Extremely high P/E ratio of 569.85 and Price/Sales of 11.16 suggest severe overvaluation
Negative earnings trend with -83.5% Q/Q EPS growth and inconsistent earnings surprises
Graham Number ($5.54) is far below current price ($74.08), indicating deep undervaluation of intrinsic worth
LEGN BEARISH

LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.

Strengths
Strong YoY revenue growth of 64.20%
Low Debt/Equity ratio of 0.41
Healthy liquidity with a Current Ratio of 1.96
Risks
Critical Piotroski F-Score (1/9) indicating fundamental weakness
Severe technical breakdown with 0/100 trend score
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Compare Another Pair

BLLN vs LEGN: Head-to-Head Comparison

This page compares BillionToOne, Inc. (BLLN) and Legend Biotech Corporation (LEGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile